STMN1 and prostate carcinoma: In the only study addressing STMN1 phosphorylation in prostate cancer, Jurmeister et al. reported that the MELK kinase inhibitor OTS167 decreased S16 and S38 phosphorylation in C4-2b PCa cells, as determined by Phospho Explorer Antibody Arrays; however, the function of S16 and S38 phosphorylation in regulating C4-2b cell growth or metastasis was not addressed [15].